HC Wainwright Issues Pessimistic Outlook for COYA Earnings

Coya Therapeutics, Inc. (NASDAQ:COYA) – Investment analysts at HC Wainwright cut their Q1 2026 EPS estimates for Coya Therapeutics in a report issued on Monday, March 23rd. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.39) for the quarter, down from their prior estimate of ($0.33). HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Coya Therapeutics’ Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.41) EPS, Q4 2026 earnings at ($0.43) EPS and FY2026 earnings at ($1.64) EPS.

A number of other equities analysts also recently issued reports on COYA. Wall Street Zen downgraded shares of Coya Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Wednesday, January 21st. Chardan Capital reaffirmed a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research report on Monday, March 16th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $15.00 target price on shares of Coya Therapeutics in a report on Monday, March 16th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Coya Therapeutics Stock Performance

NASDAQ COYA opened at $4.18 on Wednesday. Coya Therapeutics has a one year low of $3.94 and a one year high of $7.75. The company has a market capitalization of $98.06 million, a price-to-earnings ratio of -3.29 and a beta of 0.23. The company’s 50-day simple moving average is $4.66 and its two-hundred day simple moving average is $5.46.

Coya Therapeutics (NASDAQ:COYA) last issued its earnings results on Monday, March 16th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.26). The firm had revenue of $3.96 million during the quarter, compared to analysts’ expectations of $1.93 million. Coya Therapeutics had a negative return on equity of 62.76% and a negative net margin of 267.13%.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Prosperity Wealth Management Inc. grew its stake in shares of Coya Therapeutics by 16.4% during the third quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock worth $136,000 after acquiring an additional 3,350 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in Coya Therapeutics in the 3rd quarter worth approximately $28,000. CIBC Private Wealth Group LLC acquired a new stake in Coya Therapeutics in the 4th quarter worth approximately $47,000. Occudo Quantitative Strategies LP purchased a new stake in Coya Therapeutics during the 4th quarter worth approximately $66,000. Finally, Lantern Wealth Advisors LLC purchased a new stake in Coya Therapeutics during the 3rd quarter worth approximately $66,000. 39.75% of the stock is owned by institutional investors and hedge funds.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.